Role of stanniocalcin‑1 in breast cancer (Review)
- Authors:
- Fengxia Chen
- Zhicai Zhang
- Feifei Pu
-
Affiliations: Department of Medical Oncology, General Hospital of The Yangtze River Shipping, Wuhan, Hubei 430010, P.R. China, Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Orthopedics, Wuhan No. 1 Hospital, Wuhan Integrated Traditional Chinese Medicine and Western Medicine Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China - Published online on: August 22, 2019 https://doi.org/10.3892/ol.2019.10777
- Pages: 3946-3953
-
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Genome Atlas Network, . Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
De Abreu FB, Wells WA and Tsongalis GJ: The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine. Am J Pathol. 183:1075–1083. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Redig AJ and McAllister SS: Breast cancer as a systemic disease: A view of metastasis. J Intern Med. 274:113–126. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshiko Y and Aubin JE: Stanniocalcin 1 as a pleiotropic factor in mammals. Peptides. 25:1663–1669. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Chang AC, Janosi J, Hulsbeek M, de Jong D, Jeffrey KJ, Noble JR and Reddel RR: A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol. 112:241–247. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Chang AC, Jeffrey KJ, Tokutake Y, Shimamoto A, Neumann AA, Dunham MA, Cha J, Sugawara M, Furuichi Y and Reddel RR: Human stanniocalcin (STC): Genomic structure, chromosomal localization, and the presence of CAG trinucleotide repeats. Genomics. 47:393–398. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Jellinek DA, Chang AC, Larsen MR, Wang X, Robinson PJ and Reddel RR: Stanniocalcin 1 and 2 are secreted as phosphoproteins from human fibrosarcoma cells. Biochem J. 350:453–461. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Olsen HS, Cepeda MA, Zhang QQ, Rosen CA, Vozzolo BL and Wagner GF: Human stanniocalcin: A possible hormonal regulator of mineral metabolism. Proc Natl Acad Sci USA. 93:1792–1796. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Deol HK, Varghese R, Wagner GF and Dimattia GE: Dynamic regulation of mouse ovarian stanniocalcin expression during gestation and lactation. Endocrinology. 141:3412–3421. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Chang AC, Jellinek DA and Reddel RR: Mammalian stanniocalcins and cancer. Endocr Relat Cancer. 10:359–373. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Stasko SE and Wagner GF: Stanniocalcin gene expression during mouse urogenital development: A possible role in mesenchymal-epithelial signalling. Dev Dyn. 220:49–59. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang KZ, Westberg JA, Paetau A, von Boguslawsky K, Lindsberg P, Erlander M, Guo H, Su J, Olsen HS and Andersson LC: High expression of stanniocalcin in differentiated brain neurons. Am J Pathol. 153:439–445. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
He LF, Wang TT, Gao QY, Zhao GF, Huang YH, Yu LK and Hou YY: Stanniocalcin-1 promotes tumor angiogenesis through up-regulation of VEGF in gastric cancer cells. J Biomed Sci. 18:392011. View Article : Google Scholar : PubMed/NCBI | |
|
Yeung BH, Law AY and Wong CK: Evolution and roles of stanniocalcin. Mol Cell Endocrinol. 349:272–280. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH and Liu J: Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst. 102:812–827. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Du YZ, Gu XH, Li L and Gao F: The diagnostic value of circulating stanniocalcin-1 mRNA in non-small cell lung cancer. J Surg Oncol. 104:836–840. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Han J, Jeon M, Shin I and Kim S: Elevated STC-1 augments the invasiveness of triple-negative breast cancer cells through activation of the JNK/c-Jun signaling pathway. Oncol Rep. 36:1764–1771. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Murai R, Tanaka M, Takahashi Y, Kuribayashi K, Kobayashi D and Watanabe N: Stanniocalcin-1 promotes metastasis in a human breast cancer cell line through activation of PI3K. Clin Exp Metastasis. 31:787–794. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jeon M, Han J, Nam SJ, Lee JE and Kim S: STC-1 expression is upregulated through an Akt/NF-κB-dependent pathway in triple-negative breast cancer cells. Oncol Rep. 36:1717–1722. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chang AC, Doherty J, Huschtscha LI, Redvers R, Restall C, Reddel RR and Anderson RL: STC1 expression is associated with tumor growth and metastasis in breast cancer. Clin Exp Metastasis. 32:15–27. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y and Zhai X: The correlation between the expression level of STC1 and the pathological parameters of breast cancer metastasis and chemotherapy resistance. J Clin Pathol Res. 36:1585–1588. 2016.(In Chinese). | |
|
McCudden CR, Majewski A, Chakrabarti S and Wagner GF: Co-localization of stanniocalcin-1 ligand and receptor in human breast carcinomas. Mol Cell Endocrinol. 213:167–172. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zandberga E, Zayakin P, Ābols A, Pūpola D, Trapencieris P and Linē A: Depletion of carbonic anhydrase IX abrogates hypoxia-induced overexpression of stanniocalcin-1 in triple negative breast cancer cells. Cancer Biol Ther. 18:596–605. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wascher RA, Huynh KT, Giuliano AE, Hansen NM, Singer FR, Elashoff D and Hoon DS: Stanniocalcin-1: A novel molecular blood and bone marrow marker for human breast cancer. Clin Cancer Res. 9:1427–1435. 2003.PubMed/NCBI | |
|
Brantley KD, Kjærsgaard A, Cronin-Fenton D, Yacoub R, Nielsen AS, Lauridsen KL, Hamilton-Dutoit S and Lash TL: Stanniocalcin expression as a predictor of late breast cancer recurrence. Cancer Epidemiol Biomarkers Prev. 27:653–659. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li JT, Li H and Hu GH: The expression of STC1 is related to lung metastasis in breast cancer. Fudan Univ J Med Sci. 42:618–622. 2015.(In Chinese). | |
|
Joensuu K, Heikkilä P and Andersson LC: Tumor dormancy: Elevated expression of stanniocalcins in late relapsing breast cancer. Cancer Lett. 265:76–83. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Welcsh PL, Lee MK, Gonzalez-Hernandez RM, Black DJ, Mahadevappa M, Swisher EM, Warrington JA and King MC: BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci USA. 99:7560–7565. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Chang AC and Reddel RR: Identification of a second stanniocalcin cDNA in mouse and human: Stanniocalcin 2. Mol Cell Endocrinol. 141:95–99. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
DiMattia GE, Varghese R and Wagner GF: Molecular cloning and characterization of stanniocalcin-related protein. Mol Cell Endocrinol. 146:137–140. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Ishibashi K, Miyamoto K, Taketani Y, Morita K, Takeda E, Sasaki S and Imai M: Molecular cloning of a second human stanniocalcin homologue (STC2). Biochem Biophys Res Commun. 250:252–258. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
White KE, Biber J, Murer H and Econs MJ: Chromosomal localization of two human genes involved in phosphate homeostasis: The type IIb sodium-phosphate cotransporter and stanniocalcin-2. Somat Cell Mol Genet. 24:357–362. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Moore EE, Kuestner RE, Conklin DC, Whitmore TE, Downey W, Buddle MM, Adams RL, Bell LA, Thompson DL, Wolf A, et al: Stanniocalcin 2: Characterization of the protein and its localization to human pancreatic alpha cells. Horm Metab Res. 31:406–414. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ, Gaddis S, MacLeod MC and Aldaz CM: Effects of estrogen on global gene expression: Identification of novel targets of estrogen action. Cancer Res. 60:5977–5983. 2000.PubMed/NCBI | |
|
Bouras T, Southey MC, Chang AC, Reddel RR, Willhite D, Glynne R, Henderson MA, Armes JE and Venter DJ: Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res. 62:1289–1295. 2002.PubMed/NCBI | |
|
Raulic S, Ramos-Valdes Y and Dimattia GE: Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro. J Endocrinol. 197:517–529. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Iwao K, Matoba R, Ueno N, Ando A, Miyoshi Y, Matsubara K, Noguchi S and Kato K: Molecular classification of primary breast tumors possessing distinct prognostic properties. Hum Mol Genet. 11:199–206. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamura J, Miyoshi Y, Tamaki Y, Taguchi T, Iwao K, Monden M, Kato K and Noguchi S: mRNA expression level of estrogen-inducible gene, alpha 1-antichymotrypsin, is a predictor of early tumor recurrence in patients with invasive breast cancers. Cancer Sci. 95:887–892. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Esseghir S, Kennedy A, Seedhar P, Nerurkar A, Poulsom R, Reis-Filho JS and Isacke CM: Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. Clin Cancer Res. 13:3164–3173. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Coulson-Gilmer C, Humphries MP, Sundara Rajan S, Droop A, Jackson S, Condon A, Cserni G, Jordan LB, Jones LJ, Kanthan R, et al: Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer. J Pathol Clin Res. 4:241–249. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Takabatake Y, Oxvig C, Nagi C, Adelson K, Jaffer S, Schmidt H, Keely PJ, Eliceiri KW, Mandeli J and Germain D: Lactation opposes pappalysin-1-driven pregnancy-associated breast cancer. EMBO Mol Med. 8:388–406. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Argente J, Chowen JA, Pérez-Jurado LA, Frystyk J and Oxvig C: One level up: Abnormal proteolytic regulation of IGF activity plays a role in human pathophysiology. EMBO Mol Med. 9:1338–1345. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mansfield AS, Visscher DW, Hart SN, Wang C, Goetz MP, Oxvig C and Conover CA: Pregnancy-associated plasma protein-A expression in human breast cancer. Growth Horm IGF Res. 24:264–267. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ryan AJ, Napoletano S, Fitzpatrick PA, Currid CA, O'Sullivan NC and Harmey JH: Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer. Br J Cancer. 101:278–286. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Oxvig C: The role of PAPP-A in the IGF system: Location, location, location. J Cell Commun Signal. 9:177–187. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, et al: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 109:123–139. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 486:364–352. 2012. View Article : Google Scholar | |
|
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 121:2750–2767. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Stevens KN, Vachon CM and Couch FJ: Genetic susceptibility to triple-negative breast cancer. Cancer Res. 73:2025–2030. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cleator S, Heller W and Coombes RC: Triple-negative breast cancer: Therapeutic options. Lancet Oncol. 8:235–244. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Huang S, Chi Y, Qin Y, Wang Z, Xiu B, Su Y, Guo R, Guo L, Sun H, Zeng C, et al: CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription. Theranostics. 8:2549–2564. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Osborne CK: Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 51:227–238. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Osborne CK, Yochmowitz MG, Knight WA III and McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 46 (Suppl 12):S2884–S2888. 1980. View Article : Google Scholar | |
|
Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al: AJCC Cancer Staging Manua[M]8th. New York, NY: Springer; 2017 | |
|
Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B and King MC: Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 250:1684–1689. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:66–71. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B: A model for p53-induced apoptosis. Nature. 389:300–305. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Guo F, Li Y, Wang J, Li Y, Li Y and Li G: Stanniocalcin1 (STC1) inhibits cell proliferation and invasion of cervical cancer cells. PLoS One. 8:e539892013. View Article : Google Scholar : PubMed/NCBI | |
|
Daniel AR and Lange CA: Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells. Proc Natl Acad Sci USA. 106:14287–14292. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Liu R, Wei S, Chen J and Xu S: Mesenchymal stem cells in lung cancer tumor microenvironment: Their biological properties, influence on tumor growth and therapeutic implications. Cancer Lett. 353:145–152. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Shirakawa M, Fujiwara Y, Sugita Y, Moon JH, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Mori M and Doki Y: Assessment of stanniocalcin-1 as a prognostic marker in human esophageal squamous cell carcinoma. Oncol Rep. 27:940–946. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ito Y, Zemans R, Correll K, Yang IV, Ahmad A, Gao B and Mason RJ: Stanniocalcin-1 is induced by hypoxia inducible factor in rat alveolar epithelial cells. Biochem Biophys Res Commun. 452:1091–1097. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Durukan Tolvanen A, Westberg JA, Serlachius M, Chang AC, Reddel RR, Andersson LC and Tatlisumak T: Stanniocalcin 1 is important for poststroke functionality, but dispensable for ischemic tolerance. Neuroscience. 229:49–54. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lal A, Peters H, St Croix B, Haroon ZA, Dewhirst MW, Strausberg RL, Kaanders JH, van der Kogel AJ and Riggins GJ: Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst. 93:1337–1343. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang KZ, Lindsberg PJ, Tatlisumak T, Kaste M, Olsen HS and Andersson LC: Stanniocalcin: A molecular guard of neurons during cerebral ischemia. Proc Natl Acad Sci USA. 97:3637–3642. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Law AY, Ching LY, Lai KP and Wong CK: Identification and characterization of the hypoxia-responsive element in human stanniocalcin-1 gene. Mol Cell Endocrinol. 314:118–127. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW and Ratcliffe PJ: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 94:8104–8109. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:5830–5835. 1999.PubMed/NCBI | |
|
Harris AL: Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI |
